

Office Action Summary

Application No.

10/771,620

Applicant(s)

GRAFF ET AL.

Examiner

PETER J. REDDIG

Art Unit

1642

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 5 March 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1,3,8,9,66-69,71 and 72 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1,3,8,9,66-69,71 and 72 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date 7/16/2004
- 4) ☒ Interview Summary (PTO-413)
Paper No(s)/Mail Date 20080305
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

1. The amendment received March 5, 2008 in response to the Office Action of July 10, 2007 has been received and is entered.
2. Upon review and reconsideration, the finality of the previous action will be vacated and prosecution of application 10/771,620 is reopened.
3. Claims 1, 3, 8, and 9 have been amended, claims 2, 4-7, 10-65 have been cancelled, and new claims 66-69, 71, and 72 have been added.
4. Claims 1, 3, 8, 9, 66-69, 71, and 72 are pending and under consideration.

Rejections Maintained

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

5. Claims 1, 3, 8, and 9 remain rejected and claims 66-69, 71, and 72 are rejected under 35 U.S.C. 112, first paragraph, for the reasons previously set forth in section 5, pages 4-6 of the Office Action of July 10, 2007.

Applicants argue that the claims are in condition for allowance.

Applicants arguments have been considered, but have not been found persuasive upon reconsideration as the claims are not limited to detecting SEQ ID NO: 3 or SEQ ID NO: 4 or the full-length complement of either as the alternative language of claim 1 still reads on the variants encompassed by FLJ20174. Thus, the claims remain rejected for the reasons previously set forth.

It is noted that amendment of the claims to assaying the level of FLJ20174 nucleic acid selected from the group consisting of SEQ ID NO: 3 or the full length complement thereof or SEQ ID NO: 4 complement thereof or the full length or removal of the reference to FLJ20174 would obviate this rejection.

6. Claims 1, 3, 8, and 9 remain rejected and claims 66-69, 71, and 72 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement for the reasons previously set forth in section 6, pages 6-7 of the Office Action of July 10, 2007.

Applicants argue that the claims are in condition for allowance.

Applicants arguments have been considered, but have not been found persuasive upon reconsideration as the claims are not limited to detecting SEQ ID NO: 3 or SEQ ID NO: 4 or the full-length complement of either as the alternative language of claim 1 still reads on the variants encompassed by FLJ20174. Thus, the claims remain rejected for the reasons previously set forth.

It is noted that amendment of the claims to assaying the level of FLJ20174 nucleic acid selected from the group consisting of SEQ ID NO: 3 or the full length complement thereof or SEQ ID NO: 4 complement thereof or the full length or removal of the reference to FLJ20174 would obviate this rejection.

New Grounds of Rejection

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

7. Claims 71 and 72 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 71 recites the limitation "the probe" in claim 1. There is insufficient antecedent basis for this limitation in the claim.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

8. Claims 1, 3, 9, 66-69, 71, and 72 are rejected under 35 U.S.C. 102(e) as being anticipated by Tan et al (US Patent App. Publication 2005/0170351 A1, Feb. 20, 2003) as evidenced by Appendix 1 and Affymetrix (GeneChip® Data Sheet Human Genome Arrays, 2003, p. 1-4).

The claims are drawn to:

1. A method of screening for breast cancer in a subject, the method comprising obtaining a sample containing breast cells from the subject, assaying the level of FLJ20174 nucleic acid, SEQ ID NO:3 or SEQ ID NO:4 or the full length complement of either thereof, comparing the level of FLJ20174 nucleic acid, SEQ ID NO:3 or SEQ ID NO:4 or the full length complement of either thereof, in the sample from the subject with the level of FLJ20174 nucleic acid, SEQ ID NO:3 or SEQ ID NO:4 or the full length

complement of either thereof, in one or more control samples from one or more non-cancerous breast tissues, wherein an increase of at least two-fold in the level of FLJ20174, SEQ ID NO:3 or SEQ ID NO:4 or the full length complement of either thereof, in the subject sample compared to the control samples is indicative of breast cancer in the subject and wherein assaying the level comprises an amplification step.

3. The method of claim 1, wherein the one or more control breast tissue samples from a non-cancerous breast tissue are also from the subject.

9. The method of claim 1, wherein the level of FLJ20174, SEQ ID NO:3 or SEQ ID NO:4 or the full length complement thereof is determined by assaying the sample with a probe or primer consisting of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more contiguous nucleotides of SEQ ID NO:3 or SEQ ID NO:4, or the full length complement thereof.

66. The method of claim 1, wherein the step of assaying comprises a polymerase chain reaction step.

67. The method of claim 1, wherein the step of assaying comprises a reverse transcriptase polymerase chain reaction step.

68. The method of claim 1, wherein the step of assaying comprises a DNA to DNA hybridization step.

69. The method of claim 1, wherein the step of assaying comprises a DNA to RNA hybridization step.

71. The method of claim 1, wherein the probe is affixed to a solid support.

72. The method of claim 71, wherein the solid support is a membrane, a microtiter plate, or a polystyrene bead.

Tan et al. teach the identification of FLJ20174 nucleic acid by microarray analysis using Affymetrix U133A Genechips of breast tumors samples as a gene expressed in ER negative type 2 tumors, where its expression is changed at least two fold compared to other samples including normal samples, see para. 0198-0224 and Table ER-subtype II. Tan et al. teach that all tumor and normal tissues were simultaneously harvested during surgical excision of the tumor, see 0124. Tan et al. teach that the RNA used for hybridization to the cDNA microarrays was generated from RNA of the samples after a single linear amplification step, see 0126. Tan et al. teach that PCR can be used to amplify mRNA with the prior conversion of the RNA to cDNA, which is reverse transcription, for the PCR amplification, which is well known in the art to comprise DNA to DNA hybridization, for detection of the polynucleotides of the invention, see para.0030, 0035, and 0051-0055. Tan et al. teach detection of the nucleic acids with cDNA probes, see para. 0051 and 0052. Tan et al. teach using probes affixed to solid supports, such as membranes and beads for detecting nucleic acids, see para. 0055-0060.

Given that Tan et al. teach using cDNAs for detecting nucleotides of the invention and FLJ20174 is a cDNA identical to SEQ ID NO: 3 (see Appendix 1), Tan et al. teach a probe that is more than 30 contiguous nucleotides of SEQ ID NO: 3.

Additionally, it is noted that the Affymetrix U133A gene chips used by Tan et al. contain 25-mer oligonucleotide arrays complementary to the polynucleotides of the genes being screened, Affymetrix (GeneChip® Data Sheet Human Genome Arrays, 2003, p. 2 and 3). Although the Tan et al. reference does not specifically state that the probes of the Affymetrix

U133A gene chips contained a probe or primer consisting of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more contiguous nucleotides of SEQ ID NO:3 or SEQ ID NO:4, given that FLJ20174 was detected using the Affymetrix U133A gene chips, which contain 25-mer oligonucleotide arrays complementary to the sequences being screened, the claimed product appears to be the same as the prior art product, absent a showing of unobvious differences. The office does not have the facilities and resources to provide the factual evidence needed in order to establish that the product of the prior art does not possess the same material, structural and functional characteristics of the claimed product in the method of claim 9. In the absence of evidence to the contrary, the burden is on the applicant to prove that the claimed product in the method of claim 9 is different from those taught by the prior art and to establish patentable differences. See *In re Best* 562F.2d 1252, 195 USPQ 430 (CCPA).

It is noted that a wherein clause in a method claim is not given weight when it simply expresses the intended result of a process step positively recited, MPEP 2111.04. Given that the method of the prior art comprises the same method steps as claimed in the instant invention, obtaining a sample containing breast cells from the subject, assaying the level of FLJ20174 nucleic acid, SEQ ID NO:3 or SEQ ID NO:4 or the full length complement of either thereof, comparing the level of FLJ20174 nucleic acid, SEQ ID NO:3 or SEQ ID NO:4 or the full length complement of either thereof, in the sample from the subject with the level of FLJ20174 nucleic acid, SEQ ID NO:3 or SEQ ID NO:4 or the full length complement of either thereof, in one or more control samples from one or more non-cancerous breast tissues and comprising an amplification step, the claimed method is anticipated because the method will inherently be a method of screening for breast cancer, wherein an increase of at least two-fold in the level of

FLJ20174, SEQ ID NO:3 or SEQ ID NO:4 or the full length complement of either thereof, in the subject sample compared to the control samples is indicative of breast cancer in the subject. See Ex parte Novitski 26 USPQ 1389 (BPAI 1993). Although the reference does not specifically state that an increase of at least two-fold in the level of FLJ20174, SEQ ID NO: 3 or SEQ ID NO: 4 or the full length complement of either thereof, in the subject sample compared to the control samples is indicative of breast cancer in the subject, the claimed method appears to be the same as the prior art method, absent a showing of unobvious differences. The office does not have the facilities and resources to provide the factual evidence needed in order to establish that the method of the prior art does not possess the same material, structural and functional characteristics of the claimed method. In the absence of evidence to the contrary, the burden is on the applicant to prove that the claimed method is different from those taught by the prior art and to establish patentable differences. See *In re Best* 562F.2d 1252, 195 USPQ 430 (CCPA).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.

3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

9. Claim 8 is rejected under 35 U.S.C. 103(a) as being unpatentable over Tan et al (US Patent App. Publication 2005/0170351 A1, Feb. 20, 2003) as applied to claims 1, 3, 9, and 66-69, 71, and 72 above, in view of Hung et al.(US Pat. No. 6,638, 727, January 26, 1999).

Claim 8 is drawn to the method of claim 1, wherein the subject sample comprises nipple aspirate or ductal fluid obtained from the subject.

Tan et al. teach as set forth above, but do not teach nipple aspirate or ductal fluid obtained from the subject.

Hung et al teach that nipple aspirate fluid is a promising non-invasive method to identify cellular markers of breast cancer risk, see Col 2, line 60 to Col. 3, line 5. Hung et al teach using ductal fluid by nipple aspiration for the identification of the breast cancer cells, see col. 3 and 4.

It would be *prime facie* obvious to one of skill in the art at the time the invention was made to use nipple aspirate or ductal fluid from the subject as the sample to assay the level of FLJ20174 nucleic acid because these are typical samples used in the art to screen for breast

Art Unit: 1643

cancer as taught by Hung et al. One of skill in the art would have been motivated with a reasonable expectation of success to use these types of samples because they were normally used in the art for breast cancer detection.

10. No claims allowed.

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PETER J. REDDIG whose telephone number is (571)272-9031. The examiner can normally be reached on M-F 8:30 a.m.-5:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Helms Larry can be reached on (571) 272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Peter J Reddig/
Examiner, Art Unit 1642
/P. J. R./

Art Unit: 1643

/Karen A Canella/

Primary Examiner, Art Unit 1643

Appendix 1

AK000181
 LOCUS AK000181 4669 bp mRNA linear PRI 12-SEP-2006
 DEFINITION Homo sapiens cDNA FLJ20174 fis, clone COL09863.
 ACCESSION AK000181
 VERSION AK000181.1 GI:7020098
 KEYWORDS FLI_CDNA; oligo capping; fis (full insert sequence).
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
 Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Kawabata,A., Hikiji,T., Kobatake,N., Inagaki,H., Ikema,Y.,
 Okamoto,S., Okitani,R., Ota,T., Suzuki,Y., Obayashi,M., Nishi,T.,
 Shibahara,T., Tanaka,T., Nakamura,Y., Isogai,T. and Sugano,S.
 TITLE NEDO human cDNA sequencing project
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 4669)
 AUTHORS Sugano,S., Suzuki,Y., Ota,T., Obayashi,M., Nishi,T., Isogai,T.,
 Shibahara,T., Tanaka,T. and Nakamura,Y.
 TITLE Direct Submission
 JOURNAL Submitted (15-FEB-2000) Sumio Sugano, Institute of Medical Science,
 University of Tokyo, Deptment of Virology; Shirokane-dai, 4-6-1,
 Minato-ku, Tokyo 108-8639, Japan (E-mail:flcdna@ims.u-tokyo.ac.jp,
 Tel:81-3-5449-5286, Fax:81-3-5449-5416)

COMMENT NEDO human cDNA sequencing project supported by Ministry of
 International Trade and Industry of Japan; cDNA full insert
 sequencing: Research Association for Biotechnology; cDNA library
 construction, 5'- & 3'-end one pass sequencing: Department of
 Virology and Human Genome Center, Institute of Medical Science,
 University of Tokyo (partly supported by Science and Technology
 Agency).

FEATURES
 source Location/Qualifiers
 1. .4669
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="COL09863"
 /tissue_type="colon"
 /clone_lib="COL"
 /note="cloning vector pME18SFL3"
 CDS 377. .2860
 /note="unnamed protein product"
 /codon_start=1
 /protein_id="BAA90994.1"

Art Unit: 1643

```

/db_xref="GI:7020099"
/translation="MRGCLRLLALLCALPWLALLAASPGHPAKSPRQPPAPRRDPFDAAR
GADFDHVGVSIVNLSTENIYSPNYTSQPDQVTAVRVYVNSSSEHNLNYPVLVVRQKE
VLSWQVPLLFQGLYQRSYNYEVSRTLCPSSEATNETGPIQLLI FVDVASMALPGAQYK
LLVTKLKHFLQRLTNVAFHFTASPSQPOFLYKFKPDVDVSVIIKVSEMAYPECVSVSVQ
NIMCPVYLDLHNVEFNHGVYQSMTKKAAITLQKKDFPGEQFVVFVKIPEDYACGGGFF
IQEKENQTNWLRKKNLEVTIVPSIKESVYKSSLFQVFI FLSPYLGCLLVGFVHYLR
FORKSIDGSGFGSDGSGNMVASHPIAASPEGSNYGTIDESSSSPGRQMSSDGGPPG
QSDTDSVEESDFDTMPDIEKDNIIRTKMFLYLDLSLRKDRIRVSKKIKYIFWNIIIT
IAVFVLAFLVQLVITYQTVMVNTGNQDICYNFLCAHPLGVLSAFNINILNHLGHVLLG
FLFLILVLRRLDILHRRALEAKDIFAVEYGI PKHFGLEFYANGIALMMEGVLSACYHVCP
NYSNFRFDTSMFYMIAGLCMLKLYQTRHPIDINASAYASAYFAVVIMVTVLGVVFGKI
DVWFVVFISAIHVLAALSLSTIYYNMRFKIDLGIFRRAMVFTDCIQCCSRFLYMD
RMVLLVGNLNVNWSFALFGLIYRPRDFASYMLGIFICINLLLYLAFYIIMKLRSSKVL
FVFLFCIVATAMWAAALYFFQNLSSWEGTFAESREKNREICILLDFDDHDHWHFLS
ATALFFSFLVLLTLDDDLVVRDQIVF"
```

ORIGIN

Query Match		100.0%;	Score 4669;	DB 5;	Length 4669;
Best Local Similarity		100.0%;	Pred. No. 0;		
Matches	4669;	Conservative	0;	Mismatches	0;
				Indels	0;
					Gaps
					0;
Qy	1	TTTTATTATTGCTGTTATTGAGGTTGAGGGAGAAGAGATCGGCTAAATTCGCTGGG	60		
Db	1	TTTTATTATTGCTGTTATTGAGGTTGAGGGAGAAGAGATCGGCTAAATTCGCTGGG	60		
Qy	61	TAAGTGGGGGATTCTCGGCGATGAGAAACGGGGGACTTAGAAGCCGGAGGAAAATCAGC	120		
Db	61	TAAGTGGGGGATTCTCGGCGATGAGAAACGGGGGACTTAGAAGCCGGAGGAAAATCAGC	120		
Qy	121	AGCCCCACATCTCCACTTCTCCAGTCCGCCCTACTCTCCACCGTGACCTCCAGTGGAGA	180		
Db	121	AGCCCCACATCTCCACTTCTCCAGTCCGCCCTACTCTCCACCGTGACCTCCAGTGGAGA	180		
Qy	181	CCCCAGGCGGCAGCATCAGTATTGTATCGGCCCTTCGTGAGCAGCGTGCCAGCCCTGGCC	240		
Db	181	CCCCAGGCGGCAGCATCAGTATTGTATCGGCCCTTCGTGAGCAGCGTGCCAGCCCTGGCC	240		
Qy	241	GGCTGGGTCGCCAGGCATCACC CGCTCGGCTCTGAAGCGGACGCCTGCCCTGCACCGG	300		
Db	241	GGCTGGGTCGCCAGGCATCACC CGCTCGGCTCTGAAGCGGACGCCTGCCCTGCACCGG	300		
Qy	301	GCTTTGGAAGGACCTCTCTGCGCTCGCCCTCCCCAGGGTGCGCTTCGCTGAGGCC	360		
Db	301	GCTTTGGAAGGACCTCTCTGCGCTCGCCCTCCCCAGGGTGCGCTTCGCTGAGGCC	360		
Qy	361	GGGCGGGCGGCCACCATGCGCGGCTGCGTGGGCTCGCGCTGCTCTGCGGCTGCCCTG	420		
Db	361	GGGCGGGCGGCCACCATGCGCGGCTGCGTGGGCTCGCGCTGCTCTGCGGCTGCCCTG	420		
Qy	421	GCTCTGCTGGCGGCGCTGCGCCGGGACCCGGCGAAATCCCCAGGCAGCCCCGGCAC	480		
Db	421	GCTCTGCTGGCGGCGCTGCGCCGGGACCCGGCGAAATCCCCAGGCAGCCCCGGCAC	480		
Qy	481	GCGCGCGGACCCCTTCGACGCTGCCAGGGGCGCCGATTTCGATCATGTCTACAGCGGGT	540		
Db	481	GCGCGCGGACCCCTTCGACGCTGCCAGGGGCGCCGATTTCGATCATGTCTACAGCGGGT	540		
Qy	541	GGTGAACCTCAGCACCGAGAACATCTACTCTTTCAACTACACGAGCAGCCCCGACAGT	600		

Art Unit: 1643

Db	541	GGTGAACCTCAGCACCGAGAACATCTACTCTTTCAACTACACCAGCCAGCCGACCAAGGT	600
Qy	601	GACAGCCGTGAGGGTGTATGTGAACAGTTCTCTGAGAATCTCAACTACCCGGTCTCTGT	660
Db	601	GACAGCCGTGAGGGTGTATGTGAACAGTTCTCTGAGAATCTCAACTACCCGGTCTCTGT	660
Qy	661	TGTGGTTTCGCCAGCAGAAAGAGGTGCTGTCTGGCAGGTTCTCTGCTCTTCCAAGGACT	720
Db	661	TGTGGTTTCGCCAGCAGAAAGAGGTGCTGTCTGGCAGGTTCTCTGCTCTTCCAAGGACT	720
Qy	721	ATACCAGAGGAGCTACAATTATCAAGAAGTGAGCCGACCTTATGTCCCTCAGAAGCAAC	780
Db	721	ATACCAGAGGAGCTACAATTATCAAGAAGTGAGCCGACCTTATGTCCCTCAGAAGCAAC	780
Qy	781	CAATGAGACGGGACCTTGCAGCAACTGATATTTGTAGATGTGCGATCCATGGCACCCCT	840
Db	781	CAATGAGACGGGACCTTGCAGCAACTGATATTTGTAGATGTGCGATCCATGGCACCCCT	840
Qy	841	GGTGCTCAGTACAACTGCTAGTTACCAAGCTGAAGCACTTCCAGCTCCGGACAAATGT	900
Db	841	GGTGCTCAGTACAACTGCTAGTTACCAAGCTGAAGCACTTCCAGCTCCGGACAAATGT	900
Qy	901	TGCCTTTCACTTTACTGCCAGCCCTCTCAACCTCAGTATTTCTATACAAGTTTCCAA	960
Db	901	TGCCTTTCACTTTACTGCCAGCCCTCTCAACCTCAGTATTTCTATACAAGTTTCCAA	960
Qy	961	AGACGTGGACTCAGTTATCATTTAAAGTGGTGTCTGAAATGGCTTATCCATGTTCTGTGT	1020
Db	961	AGACGTGGACTCAGTTATCATTTAAAGTGGTGTCTGAAATGGCTTATCCATGTTCTGTGT	1020
Qy	1021	CTCAGTCCAGAATATCATGTGCCCGGTGTATGATCTCGACCACAATGTGGAATTTAATGG	1080
Db	1021	CTCAGTCCAGAATATCATGTGCCCGGTGTATGATCTCGACCACAATGTGGAATTTAATGG	1080
Qy	1081	TGCTATCAGTCCATGACCAAGAAAGCTGCCATCACGCTACAGAAGAAGGATTTTCCAGG	1140
Db	1081	TGCTATCAGTCCATGACCAAGAAAGCTGCCATCACGCTACAGAAGAAGGATTTTCCAGG	1140
Qy	1141	CGAGCAGTTCTTCGTGGTATTTGTGATAAAGCCTGAAGATTATGCCTGTGGAGGATCTTT	1200
Db	1141	CGAGCAGTTCTTCGTGGTATTTGTGATAAAGCCTGAAGATTATGCCTGTGGAGGATCTTT	1200
Qy	1201	CTTCATCCAGGAAAAGGAAAACAGACCTGGAATCTACAGCGAAAAAGAACCTTGAAGT	1260
Db	1201	CTTCATCCAGGAAAAGGAAAACAGACCTGGAATCTACAGCGAAAAAGAACCTTGAAGT	1260
Qy	1261	GACCATTGTCCCTTCCATTAAAGAATCTGTTTATGTGAAATCCAGTCTTTTCAGTGTCTT	1320
Db	1261	GACCATTGTCCCTTCCATTAAAGAATCTGTTTATGTGAAATCCAGTCTTTTCAGTGTCTT	1320
Qy	1321	CATCTTCTGTCCCTTCTACTTGGGATGCCCTTCTGTTGGGTTTGTTTCATTATCTGAGGTT	1380
Db	1321	CATCTTCTGTCCCTTCTACTTGGGATGCCCTTCTGTTGGGTTTGTTTCATTATCTGAGGTT	1380
Qy	1381	TCAGAGAAAATCCATTGATGGAAGCTTTGGGTCCAATGATGGCTCTGGAAAATATGGTGGC	1440
Db	1381	TCAGAGAAAATCCATTGATGGAAGCTTTGGGTCCAATGATGGCTCTGGAAAATATGGTGGC	1440
Qy	1441	ATCTCATCCCATTTGCTGCCAGCACACCCGAGGGAGCAATTATGGGACAAATAGATGAGTC	1500

Art Unit: 1643

Db	1441	ATCTCATCCCATTTGCTGCCAGCACACCCGAAGGGAGCAATTATGGGCAATAGATGAGTC	1500
Qy	1501	AAGCTCCAGTCTCTGGAAGGCAGATGTCTCTCCGATGGTGGGCCACCGGGCCAGTCAGA	1560
Db	1501	AAGCTCCAGTCTCTGGAAGGCAGATGTCTCTCCGATGGTGGGCCACCGGGCCAGTCAGA	1560
Qy	1561	CACAGACAGCTCCGTGGAGGAGAGCGCACTTCGACACCATGCCAGACATTGAGAGTGATAA	1620
Db	1561	CACAGACAGCTCCGTGGAGGAGAGCGCACTTCGACACCATGCCAGACATTGAGAGTGATAA	1620
Qy	1621	AAACATCATCCGAGACCAAGATGTTCTCTTACCTGTGTCAGATTGTGCAGGAAGGACCGGAG	1680
Db	1621	AAACATCATCCGAGACCAAGATGTTCTCTTACCTGTGTCAGATTGTGCAGGAAGGACCGGAG	1680
Qy	1681	AATTGTGACGAAAAAATATAAAAATTTATTTTGGACATCATCACCATTCGCTGTGTTTTA	1740
Db	1681	AATTGTGACGAAAAAATATAAAAATTTATTTTGGACATCATCACCATTCGCTGTGTTTTA	1740
Qy	1741	CGCGCTGCCCGTGATCCAGCTGGTCATTACCTATCAGACAGTGGTAAATGTCACCTGGCAA	1800
Db	1741	CGCGCTGCCCGTGATCCAGCTGGTCATTACCTATCAGACAGTGGTAAATGTCACCTGGCAA	1800
Qy	1801	CCAGGACATCTGTTACTACAACCTTCCTCTGTGCTACCCCTTGGGCGTCTCGAGTGCCCT	1860
Db	1801	CCAGGACATCTGTTACTACAACCTTCCTCTGTGCTACCCCTTGGGCGTCTCGAGTGCCCT	1860
Qy	1861	CAACAACATTCTCAGCAATCTGGGCCACGTCCTCTGGGCTTCCTCTCTCTGCTGATAGT	1920
Db	1861	CAACAACATTCTCAGCAATCTGGGCCACGTCCTCTGGGCTTCCTCTCTCTGCTGATAGT	1920
Qy	1921	CTTGCGCCGCGACATCTCTCATCGGAGAGCCCTGGAAGCCAAGGACATCTTTGCTGTGGA	1980
Db	1921	CTTGCGCCGCGACATCTCTCATCGGAGAGCCCTGGAAGCCAAGGACATCTTTGCTGTGGA	1980
Qy	1981	GTACGGGATTCCTCCAAACACTTTGGTCTCTTCTACGCTATGGGCATTGCATTGATGATGGA	2040
Db	1981	GTACGGGATTCCTCCAAACACTTTGGTCTCTTCTACGCTATGGGCATTGCATTGATGATGGA	2040
Qy	2041	AGGGGTGCTCAGTGCTTGTCTACCATGTCTGCCCTAATTATTCCAACCTCCGATTTCGACAC	2100
Db	2041	AGGGGTGCTCAGTGCTTGTCTACCATGTCTGCCCTAATTATTCCAACCTCCGATTTCGACAC	2100
Qy	2101	CTCCTTCATGTACATGATCGCTGGCCTGTGCATGCTGAAGCTCTATCAGACCCGCCACCC	2160
Db	2101	CTCCTTCATGTACATGATCGCTGGCCTGTGCATGCTGAAGCTCTATCAGACCCGCCACCC	2160
Qy	2161	AGACATCAATGCCAGCGCCTACTCTGCCTATGCCTCCCTTTGCTGTGGTCATCATGTCAC	2220
Db	2161	AGACATCAATGCCAGCGCCTACTCTGCCTATGCCTCCCTTTGCTGTGGTCATCATGTCAC	2220
Qy	2221	CGTCCTTGGAGTGGTGTTTGGAAAAAATGACGATGGTTCTGGGTCATCTTCTCTGCAAT	2280
Db	2221	CGTCCTTGGAGTGGTGTTTGGAAAAAATGACGATGGTTCTGGGTCATCTTCTCTGCAAT	2280
Qy	2281	CCAGGTTCTGGGCTCGCTAGCCCTCAGCACCCAGATATATTATATATGGGTGTTTCAAGAT	2340
Db	2281	CCAGGTTCTGGGCTCGCTAGCCCTCAGCACCCAGATATATTATATATGGGTGTTTCAAGAT	2340
Qy	2341	AGATTGGGAATTTTCGGCGGGCTGCCATGGTGTCTACACAGACTGTATCCAGCAGTG	2400

Art Unit: 1643

Db 2341 AGATTITGGGAATTTCCGGCGGGCTGCCATGGTGTCTACACAGACTGTATCCAGCAGTG 2400

Qy 2401 TAGCCGACCTCTATATATGGATAGAATGGTGTGCTGGTTGTGGGGAATCTGGTTAACTG 2460
|||||

Db 2401 TAGCCGACCTCTATATATGGATAGAATGGTGTGCTGGTTGTGGGGAATCTGGTTAACTG 2460

Qy 2461 GTCCTTCGCCCTCTTTGGATTGATATACGCCCCAGGGACTTTGCTTCCTACATGCTGGG 2520
|||||

Db 2461 GTCCTTCGCCCTCTTTGGATTGATATACGCCCCAGGGACTTTGCTTCCTACATGCTGGG 2520

Qy 2521 CATCTTCATCTGTAACCTTTTGTGTACCTGGCCTTTTACATCATCATGAAGCTCCGCGAG 2580
|||||

Db 2521 CATCTTCATCTGTAACCTTTTGTGTACCTGGCCTTTTACATCATCATGAAGCTCCGCGAG 2580

Qy 2581 CTCTGAAAAGGTCTCCAGTCCCGCTCTTCTGCATCGTGGCCACCGCTGTGATGTGGGC 2640
|||||

Db 2581 CTCTGAAAAGGTCTCCAGTCCCGCTCTTCTGCATCGTGGCCACCGCTGTGATGTGGGC 2640

Qy 2641 TGCCGCCCTATATTTTTCTTCCAGAACTCAGCAGCTGGGAGGGAATCCGGCCGAATC 2700
|||||

Db 2641 TGCCGCCCTATATTTTTCTTCCAGAACTCAGCAGCTGGGAGGGAATCCGGCCGAATC 2700

Qy 2701 CCGGGAGAAGAACCGCGAGTGCATTCTGCTGGATTCTTCGATGACCATGACATCTGGCA 2760
|||||

Db 2701 CCGGGAGAAGAACCGCGAGTGCATTCTGCTGGATTCTTCGATGACCATGACATCTGGCA 2760

Qy 2761 CTTCCTCTCTGCTACTGCTCTGTTTTCTCATTCTTGGTTTGTGTTAACTTTGGATGATGA 2820
|||||

Db 2761 CTTCCTCTCTGCTACTGCTCTGTTTTCTCATTCTTGGTTTGTGTTAACTTTGGATGATGA 2820

Qy 2821 CCTTGATGTGGTTCGGAGAGACAGATCCCTGTCTTCTGAACCTCCAACATTAAAGAGAGG 2880
|||||

Db 2821 CCTTGATGTGGTTCGGAGAGACAGATCCCTGTCTTCTGAACCTCCAACATTAAAGAGAGG 2880

Qy 2881 GGAGGGAGCGATCAATCTTGGTGTGTTTACAAAAATTACAGTGACCACAGCAAAGTAA 2940
|||||

Db 2881 GGAGGGAGCGATCAATCTTGGTGTGTTTACAAAAATTACAGTGACCACAGCAAAGTAA 2940

Qy 2941 CCACTGCCAGATGCTCCACTCACCTCTGTAGAGCCAACTCTGCATTACACAGGAAGGA 3000
|||||

Db 2941 CCACTGCCAGATGCTCCACTCACCTCTGTAGAGCCAACTCTGCATTACACAGGAAGGA 3000

Qy 3001 GAGGGGCTCGGGGAGATTAAACCTGCAAGAAAGGAGGCAGAAAGGGAGCCATGTTTGA 3060
|||||

Db 3001 GAGGGGCTCGGGGAGATTAAACCTGCAAGAAAGGAGGCAGAAAGGGAGCCATGTTTGA 3060

Qy 3061 GGACAGACGCAAACTGAGGAGCTGAGAAACACTTGTCTCTCCATCTGCAGCTTTGGGA 3120
|||||

Db 3061 GGACAGACGCAAACTGAGGAGCTGAGAAACACTTGTCTCTCCATCTGCAGCTTTGGGA 3120

Qy 3121 GTGCAACAGGGATAGGCACTGCATCCAAGTCAACTCACCATTCTGGGGTCCCTCCACCC 3180
|||||

Db 3121 GTGCAACAGGGATAGGCACTGCATCCAAGTCAACTCACCATTCTGGGGTCCCTCCACCC 3180

Qy 3181 TCACGGAGACTTGCACGCAATGGCAGAATGTGCTGCACACTTCCCTCCAGTTGTCAACC 3240
|||||

Db 3181 TCACGGAGACTTGCACGCAATGGCAGAATGTGCTGCACACTTCCCTCCAGTTGTCAACC 3240

Qy 3241 TGCCAGAAAGGCCACAGCTTGGACTTCCTGCCAGAAACTGTGTTGGCCCCCTTCACA 3300
|||||

Art Unit: 1643

Db	3241	TGCCCCAGAAAGGCCAGCAGCTTGGACTTCTCGCCAGAAACTGTGTTGGCCCCCTTCACA	3300
Qy	3301	CCTCTGCAACACCTGCTGCTCCAGCAAGAGGATGTGATTCTTTAGAATATGGCGGGGAGG	3360
Db	3301	CCTCTGCAACACCTGCTGCTCCAGCAAGAGGATGTGATTCTTTAGAATATGGCGGGGAGG	3360
Qy	3361	TGACCCAGGCGCTGCCCTACTGGGATAGATGTTTAAATGGCACCAGCTAGTCACCTCCC	3420
Db	3361	TGACCCAGGCGCTGCCCTACTGGGATAGATGTTTAAATGGCACCAGCTAGTCACCTCCC	3420
Qy	3421	AGAAGAACTCTGTACATTTCCCCCAGGTTTCTGATGCCATCAGAAGGGCTCAGGAGTGG	3480
Db	3421	AGAAGAACTCTGTACATTTCCCCCAGGTTTCTGATGCCATCAGAAGGGCTCAGGAGTGG	3480
Qy	3481	GGTTTGTACACATTCTCTTAACAAGTAACGTGCTACTGGGACCGAGTCTCTGGGTGCTTA	3540
Db	3481	GGTTTGTACACATTCTCTTAACAAGTAACGTGCTACTGGGACCGAGTCTCTGGGTGCTTA	3540
Qy	3541	CATATTCCTTCGTGCTTCTCATCTCACTGACCTGTGTGGACCTCATCACTCTGACTCTGCC	3600
Db	3541	CATATTCCTTCGTGCTTCTCATCTCACTGACCTGTGTGGACCTCATCACTCTGACTCTGCC	3600
Qy	3601	TTCTTGAAAGGCCCTGTCACTCCACAGATGTCTGGCCAGCTTCAAGGCAGAAGGAAAA	3660
Db	3601	TTCTTGAAAGGCCCTGTCACTCCACAGATGTCTGGCCAGCTTCAAGGCAGAAGGAAAA	3660
Qy	3661	CAGGAAAAGCTCTTTTAACAGCAGCAGGAACAAGAGAAATGACTAACCATATACTAAAAGAC	3720
Db	3661	CAGGAAAAGCTCTTTTAACAGCAGCAGGAACAAGAGAAATGACTAACCATATACTAAAAGAC	3720
Qy	3721	TGGTAACAGCAGCAGCAGCCAGCAGGCTCACCTTAAGGACTTGGGCTGCCAGAGCAAA	3780
Db	3721	TGGTAACAGCAGCAGCAGCCAGCAGGCTCACCTTAAGGACTTGGGCTGCCAGAGCAAA	3780
Qy	3781	TTACAGCAGAGCTTATTTGGCCTCCCATTCACACAGCTCAGTTCTGTGCCACATCACCTT	3840
Db	3781	TTACAGCAGAGCTTATTTGGCCTCCCATTCACACAGCTCAGTTCTGTGCCACATCACCTT	3840
Qy	3841	TGGGGAAGAAATCAGCATTCTAATCAGGGACACTACTTCAGGAGTCTCCACAGCGAGTC	3900
Db	3841	TGGGGAAGAAATCAGCATTCTAATCAGGGACACTACTTCAGGAGTCTCCACAGCGAGTC	3900
Qy	3901	CGTCATCTGTCACTTTATGTAGATCAGGGTTCTAGACTTCTTCCTGAGGTTCTCAGAAG	3960
Db	3901	CGTCATCTGTCACTTTATGTAGATCAGGGTTCTAGACTTCTTCCTGAGGTTCTCAGAAG	3960
Qy	3961	CAGCTCTCAGGATGAACGTATTGTCTCTTCCCCTCTTCTGCAAAAGTGACAGCTAATC	4020
Db	3961	CAGCTCTCAGGATGAACGTATTGTCTCTTCCCCTCTTCTGCAAAAGTGACAGCTAATC	4020
Qy	4021	TAATGTTGTCTCTCGGTTGCACCTGACATTCTCTCCCAGTAAGGTGTTGGCAAGCTCAG	4080
Db	4021	TAATGTTGTCTCTCGGTTGCACCTGACATTCTCTCCCAGTAAGGTGTTGGCAAGCTCAG	4080
Qy	4081	CATCTGGGTTCCACTCTCACACTGTCTGGCAGCTCTGTGCTGAGAAGTCTACATTGAC	4140
Db	4081	CATCTGGGTTCCACTCTCACACTGTCTGGCAGCTCTGTGCTGAGAAGTCTACATTGAC	4140
Qy	4141	CAGGCCCCCTTGTGCTGGAGTATGACGTAATCAGAAAAATAGACGTATAAATGTGCACA	4200

Art Unit: 1643

```

Db      4141  CAGGCCCCCTTGTTCCTGGAGTATGACGTAATCAGAAAAATAGACGTATAAATGTGCACA 4200
Qy      4201  TCGTATGTATTGCTTTGTGAAATTTAAAGTCACCTCTTGCCTCTGCTTTCTCTGATCATTC 4260
      |||
Db      4201  TCGTATGTATTGCTTTGTGAAATTTAAAGTCACCTCTTGCCTCTGCTTTCTCTGATCATTC 4260
Qy      4261  GTTAGAGAAATGGATCAGGCATTTTAAATTTATTATTTCTTCTCTAAACTATTGTCAT 4320
      |||
Db      4261  GTTAGAGAAATGGATCAGGCATTTTAAATTTATTATTTCTTCTCTAAACTATTGTCAT 4320
Qy      4321  TGTGTTCAAAAACCCATTTTAGAAGTTTGAACAGCAAGCTTTTCTGATTTTAAAAACAC 4380
      |||
Db      4321  TGTGTTCAAAAACCCATTTTAGAAGTTTGAACAGCAAGCTTTTCTGATTTTAAAAACAC 4380
Qy      4381  AAAGTGTCTTCAATGAAATATTTTGTGATTTTAAAGTCCCCAAATGTGTACTTAGC 4440
      |||
Db      4381  AAAGTGTCTTCAATGAAATATTTTGTGATTTTAAAGTCCCCAAATGTGTACTTAGC 4440
Qy      4441  CTCTGTATTCTCTTATTCTTTAAGCAGTGTGGCTTCCATTGACCATATGAAGGCCACC 4500
      |||
Db      4441  CTCTGTATTCTCTTATTCTTTAAGCAGTGTGGCTTCCATTGACCATATGAAGGCCACC 4500
Qy      4501  AATTAATGGTGTGTTAATCCACATGTAAAAAACTTTTGGCAGGGCACAGTGGCTCA 4560
      |||
Db      4501  AATTAATGGTGTGTTAATCCACATGTAAAAAACTTTTGGCAGGGCACAGTGGCTCA 4560
Qy      4561  CGCTGTAAATCCCAAGTGTGGAATTTACAGTAGGACCACCACACTTGGTCCACTTAC 4620
      |||
Db      4561  CGCTGTAAATCCCAAGTGTGGAATTTACAGTAGGACCACCACCACACTTGGTCCACTTAC 4620
Qy      4621  TTATAATAAACATTGATTTGGTCGTTAAAAAATTTTAAAAAATTTTAAAAAATTTTAAAAA 4669
      |||
Db      4621  TTATAATAAACATTGATTTGGTCGTTAAAAAATTTTAAAAAATTTTAAAAAATTTTAAAAA 4669

```

```

LOCUS      AK000181      4669 bp      mRNA      linear      PRI 22-FEB-
2000
DEFINITION Homo sapiens cDNA FLJ20174 fis, clone COL09863.
ACCESSION  AK000181
VERSION    AK000181.1 GI:7020098
KEYWORDS   oligo capping; fis (full insert sequence).
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1 (sites)
AUTHORS    Kawabata,A., Hikiji,T., Kobatake,N., Inagaki,H., Ikema,Y.,
Okamoto,S., Okitani,R., Ota,T., Suzuki,Y., Obayashi,M., Nishi,T.,
Shibahara,T., Tanaka,T., Nakamura,Y., Isogai,T. and Sugano,S.
TITLE      NEDO human cDNA sequencing project
JOURNAL    Unpublished (2000)
REFERENCE  2 (bases 1 to 4669)
AUTHORS    Sugano,S., Suzuki,Y., Ota,T., Obayashi,M., Nishi,T., Isogai,T.,
Shibahara,T., Tanaka,T. and Nakamura,Y.
TITLE      Direct Submission
JOURNAL    Submitted (15-FEB-2000) Sumio Sugano, Institute of Medical
Science,

```

Art Unit: 1643

University of Tokyo, Deptment of Virology; Shirokane-dai, 4-6-1, Minato-ku, Tokyo 108-8639, Japan (E-mail:cdnal@ims.u-tokyo.ac.jp, Tel:81-3-5449-5286, Fax:81-3-5449-5416)

COMMENT NEDO human cDNA sequencing project supported by Ministry of International Trade and Industry of Japan; cDNA full insert sequencing: Research Association for Biotechnology; cDNA library construction, 5'- & 3'-end one pass sequencing: Department of Virology and Human Genome Center, Institute of Medical Science, University of Tokyo (partly supported by Science and Technology Agency).

FEATURES

source Location/Qualifiers

1..4669

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="COL09863"

/tissue_type="colon"

/clone_lib="COL"

/note="cloning vector pME18SFL3"

CDS 377..2860

/note="unnamed protein product"

/codon_start=1

/protein_id="BA90994.1"

/db_xref="GI:7020099"

/translation="MRGCLRLALLCALFWLLLAASPGHPAKSPRQPPAPRRDPFDAAR

GADFHDVYSGVNLSTENIYSFNYSQPDQVTA VRVYVNSSSENLYPVLVVVRQQKE

VLWQVPLL FQGLYQRSYNYQEVSRITLCPSEATNETGPLQLIFVDVASMPLGAQYK

LLVTKLKHFQLRTNVAFHFTASPSQPQYFLYKFPKDVDSVLIKVVSEMAYPCSVSVQ

NIMCPVYDL DHNVEFNGVYQSMTKAAITLQKKDFPGEQFVVVFIKPEDYACGGSFF

IQEKENQTNWLQRKKNLEVTIVPSIKESVYVKSSLFSVFIFLSFYLGCLLVGFVHYLR

FQKRSIDGSFGSNDGSGNMVASHPIAAS TPEGSNYGTIDESSSSPGRQMSSSDGPPG

QSDTDSSVEESDFDTMPDIESDKNIIRTKMFLYLSDLRSKDRRIVSKKYKIYFWNIT

IAVFYALPVIQLVITYQT VVNV TGNQDICYNFLCAHPLGVLSAFNNILSNLGHVLLG

FLFLILVLRDILHRRALEAKDIFAVEYGIPKHFGLFYAMGIALMMEGVLSACYHVCP

NYSNFRFDTSFMYMIAGLCMLKLYQTRHPDINASAYSAYASFVVMVTVLGVVFGKN

DVWFVIFSAIHVLASLALSTQIYYMGRFKIDLGIFRAAMVFYTDICIQCSRPLYMD

RMVLLVVGNLVNSFALFGLIYRPRDFASYMLGIFICNLLLYLAFYIIMKLRSSKEVL

PVPLFCIVATAVMWAAALYFFPQNLSSWEGTPAESREKNRECILLDFDDHDIWHFLS

ATALFFSFLVLLTLDLDDLVVRRDQIPVF"

ORIGIN

Art Unit: 1643

```

1   tttttattat   tgctgttatt   gagggttgagg   gagaagagat   cgggtctaata   tctggctggg
61  taagttggggg   gatttctcggc   gatgagaaac   gggggactta   gaagccggag   gaaaatcagc
121 agccccacat   ctccacttct   ccagtcgcgc   ctactctcca   ccogtgacct   ccagtgga
181 cccaggcg   cagcatcagt   attgatcgg   cccttctgta   gcacgtcgcc   agccctggcc
241 ggctgggtt   gccaggcatc   accgcgtcgg   ctctgaagcg   gacgctggc   cctgcaccgg
301 gctttggaa   gacctctctc   gcgctcgccc   ctcccccagg   gtggctccgc   ttctgagccc
361 gggcgctcgg   cccaacatcg   gcggctgcct   cgcgctcgcg   ctgctctcg   cgcctccctg
421 gctcctgctg   cgcgctcgcc   ccgggacacc   gcgaaatcc   cccaggcacc   ccccgccacc
481 gcgcccgcac   cccttcgcagc   ctgccagggg   cgccgatttc   gatcatgtct   acagcggggt
541 ggtgaacctc   agcaccgaga   acatctactc   ttcaactac   ccagccagc   ccgaccaggt
601 gacagccgtg   aggggtgatg   tgaacagttc   ctctgagaat   ctcaactacc   cggctcttgt
661 tgtggttcgc   cagcagaaag   aggtgctgtc   ctggcaggtt   cctctgtctc   tccaaggact
721 ataccagag   agctacaatt   atcaagaagt   gagccgacc   ttatgtccct   cagaagcaac
781 caatgagacg   ggacccttgc   agcaactgat   atttgtatg   gtgcatacca   tggaccacct
841 ggggtgctag   tacaactgc   tagttacca   gctgaagcac   ttccagctcc   ggacaatgt
901 tgcctttcac   tttactgcca   gccctctca   acctcagtat   ttctatata   agtttcccaa
961 agacgtggac   tcagttatca   ttaaagtgtg   gctctgaagt   gcttatccat   gttctgtgtg
1021 ctcagtcag   aatatcatgt   gcccggtgta   tgaatctgac   ccaatgtgg   aatttaatgg
1081 tgtctatcag   tccatgacca   agaaagctgc   catcacgcta   cagaagaagg   attttccagg
1141 cgagcagttc   ttctgtggtat   ttgtgataaa   gctgaagat   tatgctgtg   gaggatcttt
1201 cttcatccag   gaaaaggaaa   accagacctg   gaattctacag   cgaaaaaaga   accttgaagt
1261 gaccattgtc   ccttccatta   aagaatctgt   ttatgtgaaa   tccagtcttt   tcaagtcttt
1321 ctactctctg   ctctctactc   tgggtatgct   ttgtgtggg   ttctgtccat   atctagttct
1381 tcagagaaaa   tccattgatg   gaagctttgg   gtccaatgat   ggctctggaa   atatgggtgc
1441 atctcatccc   attgtcgcca   gcacaccgga   agggagcaat   tatgggacaa   tagatgagtc
1501 aagctccagt   cctggaagcg   agatgtctc   cctcgatggt   gggccaccgg   gccagtcaga
1561 cacagacagc   tccgtggagg   agagcgactt   cgacaccatg   ccagacattg   agagtgtata
1621 aaacatcatc   cggaccaaga   tgttctctta   cctgtcagat   ttgtccagga   aggaccggag
1681 aattgtcgac   aaaaaatata   aaatttattt   ttggaacatc   ataccatttg   ctgtgtttta
1741 cgcgctggcc   gtgatccagc   tggctattac   ctatcacaga   tgggtaaaatg   tcactggcaa
1801 ccaggacatc   tgttactaca   acttctctct   tgcctacccc   ttggcgctcc   tgagtgcott
1861 caacaacatt   ctcaagaatc   tgggccaagt   gcttctgggg   ttctcttccc   tgcgtatagt
1921 cttgcgccgc   gacatctctc   atccggagagc   cctggaagcc   aaggacatct   ttgctgtgga
1981 gtacgggatt   cccaacact   ttggtctctt   ctacgctatg   ggcattgcgt   tgatgtgga
2041 aggggtgtct   agcttctgtc   acctgtctgt   cctcaattat   tccaactctc   tagtcgacac
2101 ctctctcatg   tacatgatcg   ctggcgtgtg   catgctgaag   ctctatcaga   cccgccaccc
2161 agacatcaat   gccagcgctc   actctgccta   tgctgtgtca   ctgtgtgtcc   tcatggtcag
2221 cgtccttggg   gtggtgtttg   gaaaaaatga   cgtatggttc   tgggtcatct   tctctgcaat
2281 ccaagtctct   gcctcgctag   ccctcagcac   ccagatata   tatatgggtc   gtttcaagat
2341 agattttgga   attttccggc   gggctgccaat   ggtgtcttac   acagactgta   tccagcagtg
2401 tagccagcat   ctatatatgg   atagaatggt   gtgctggtt   gtggggaact   tgggttaactg
2461 gtccttcgoc   ctatttggat   tgatatacgt   cccaggggac   ttgtactctc   acatgctggg
2521 catcttcacg   tgtaaccttt   tgcgttaacct   ggccctttac   atcatatga   agctcccgag
2581 cttgaaaaag   gtcctcccaa   tccgcctctt   ctgcactgtg   gcacccgtgc   tgaatgtggc
2641 tgcgcgccca   tattttttct   tccagaatct   ggaattctctc   gatgaccatg   acatctggca
2701 ccggggagaa   aaccgcgagt   gcaattctgct   tgttttttct   ttgttaactt   tggatgatga
2761 ctctctctct   gactctgctc   tgttttttct   atcttggttt   ttgttaactt   tgaatgatga
2821 ccttgatgtg   gttcggagag   accagatccc   tgctctctga   acctccaaca   ttaagagagg
2881 gaggaggcgc   atcaactctg   gtgctgtttc   aaaaaaata   cagtgaccac   agcaagataa
2941 ccactgccag   atgctccact   caccctctgt   agagccaact   ctgcattcac   acaggaagga
3001 gaggggctgc   gggagattta   aaactgcaag   aaaggaggca   gaaggggagc   catgttttga
3061 ggacagacgc   aaactgagg   agctgagaaa   cactgtctcc   ttccactctc   agctttggga
3121 gtgcaacagg   gataggcact   gcatccaagt   caactcacca   tcttggggtc   cctccacccc
3181 tcacggagac   ttgcagacaa   tggcagaatg   ctgctgcaca   ctccctcca   gttgtcacc

```

Art Unit: 1643

3241 tgcccagaaa ggccagcagc ttggacttcc tgcccagaaa ctgtgttggc ccccttcaca
3301 cctctgcaac acctgctgct ccagcaagag gatgtgattc tttagaatat ggcggggagg
3361 tgaccccagg ccttgcccta ctgggataga tgttttaatg gcaccagcta gtcacctccc
3421 agaagaaact ctgtacattt cccccaggtt tctgatgcca tcagaagggc tcaggagtgg
3481 ggtttgtcac acattcctct taacaagtaa ctgtcactgg gaccgagtc tgggtgctta
3541 catattcctt cgtgtcttca tctcactgac ctgtgtggac ctcatcactc tgactctgcc
3601 ttcttggaaa ggccctgtca ctccacagat gtctggccag ctccaaggca gaaggaaaaa
3661 caggaaaaagc tcttttaaca gcagcaggaa caagagaaat gactaacat actaaaagac
3721 ttggtaacagc agcagcagcc agacaggcct caccttaagg acttgggctg ccagagcaaa
3781 ttcagcagag cttatttggc ctcccattca cacagctcag ttctgtgccc acatcacctt
3841 tggggaagaa atcagcatte taatcagggg cactacttca ggagtcctcc acagcgagtc
3901 cgtcatctgt cactttatgt agatcagggt tctagacttc ttccctgagg ttctcagaag
3961 cagctctcag gatgaacgta ttgtcctctt cccctcttct tgcaaatgac acagctaate
4021 taatgtttgc tctcggttgc acctgacatt ctctccccag taaggtgttg gcaagctcag
4081 catctggggt ccactctcac actgtctggc agctctgtgt ctgagaagtt ctacattgac
4141 caggccccct tgttgctctg agtatgacgt aatcagaaaa tagacgtata aatgtgcaca
4201 tgcgtatgta tttgcttctg aaattaaagt cacctcttgc ctctgcttcc ctgatcatte
4261 gttagagaaa tggatcaggc atttttttaa attattattc ttctctaaa ctatttgcat
4321 tgtgttcaaa aaccattttt agaagtttga acagcaagct ttctctgatt ttaaaaacac
4381 aaagttgctt tcaatgaaat attttgtgat ttttttaag tcaccaaatg tgtactttagc
4441 ctctctgtat tccttattct ttaagcagtg ttggcttcca ttgacctat gaaggccacc
4501 aattaaatgg ttgtgttaat ccaacatgta aaaaaacttt ttggcaggga cagtggctca
4561 cgctgtaat cccaagtgc tggaaattac aggtaggacc accacacttg gtcacattac
4621 ttataataaa cattgatattg tgcgttaaaa aaaaaaaaa aaaaaaaaa